<?xml version="1.0" encoding="UTF-8"?>
<p>Serum samples were collected during arboviral surveillance from February 2014 to October 2018. As inclusion criteria, we sought patients presenting clinical diagnoses of dengue, Zika or chikungunya infection, who reported arbovirus-like symptoms, such as fever, myalgia, headache and arthralgia. All of them were interviewed and signed an informed consent form.</p>
